Paul J. Diaz, president and chief executive officer, Bryan Riggsbee, chief financial officer, and Dale Muzzey, chief scientific officer, presented at the 41st Annual J.P. Morgan (JPM) Healthcare Conference on Monday, Jan. 9, 2023.
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, hosted its third-quarter earnings conference call on Tuesday, Nov. 1, 2022.
Click here for presentation.
Revenue of $156.4 million for the quarter ended September 30, 2022.
Third quarter revenue, excluding div...
Results from a nationwide survey conducted on the attitudes, knowledge, and practices related to risk assessment, prevention, and screening for breast and ovari...
Myriad Genetics, Inc., (NASDAQ: MYGN), will host an Investor Day on Aug. 11, 2022, providing a strategic business update and overview of the company’s growth ...
01/31/2023 SC 13G/A
01/23/2023 SC 13G/A
“For more than 31 years, Myriad Genetics has worked to be a force for good in the world as we fulfill our mission to advance health and well-being for all. In our inaugural ESG report, we seek to convey our core values as a caring, ethical, and sustainable company committed to continuous improvement,” said Paul J. Diaz, president and CEO, Myriad Genetics. “I want to thank our 2,400 teammates for the progress we have made to date, recognizing we have more work to be done. We are committed to intensifying our ESG focus helping to address the needs of the patients, healthcare providers, stakeholders, and communities we serve.”